n (%) |
135 (100) |
102 (75.5) |
33 (24.5) |
Age: median (range) |
68 (25 - 92) |
70 (25 - 92) |
58 (30 -
83) |
<60 |
48 (35.6) |
30 (29.4) |
18 (54.6) |
61 - 70 |
25 (18.5) |
22 (21.6) |
3 (9.1) |
71 - 80 |
41 (30.4) |
33 (32.4) |
8 (24.2) |
>80 |
21 (15.6) |
17 (16.7) |
4 (12.1) |
Sex |
|
|
|
male |
81 (60) |
56 (54.9) |
25 (75.8) |
female |
54 (40) |
46 (45.1) |
8 (24.2) |
eGFR < 60 ml/min1 |
19 (14.1) |
16
(15.7 ) |
3 (9.1) |
Indication PGx panel test |
|
|
|
Clopidogrel |
60 (44.4) |
60 (58.8) |
na |
Tamoxifen |
15 (11.1) |
15 (14.7) |
na |
Polypsychopharmacotherapy |
9 (6.7) |
9 (8.8) |
na |
Opioids |
7 (5.2) |
7 (6.9) |
na |
Statins |
6 (4.4) |
6 (5.9) |
na |
Phenprocoumon |
2 (1.5) |
2 (1.9) |
na |
Chemotherapy |
2 (1.5) |
2 (1.9) |
na |
PPI |
1 (0.7) |
1 (0.9) |
na |
Pharmacotherapy |
|
|
|
Number of drugs: median (range)2
|
6 (0 - 19) |
6 (0 -
19) |
3 (0 - 14) |
Aspirin |
43 (31.9) |
38 (37.3) |
5 (15.2) |
Clopidogrel |
48 (35.6) |
48 (47.1) |
0 (0) |
Prasugrel or Ticagrelor |
1 (0.7) |
1 (0.9) |
0 (0) |
Coumarines or NOAC |
25 (18.5) |
22 (21.6) |
3 (9.1) |
Beta blockers |
44 (32.6) |
35 (34.3) |
9 (27.3) |
ACE or ARB |
60 (44.4) |
48 (47.1) |
12 (36.4) |
CCB |
20 (14.8) |
16 (15.7) |
4 (12.1) |
Diuretics |
34 (25.2) |
28 (27.5) |
6 (18.2) |
PPI |
45 (33.3) |
40 (39.2) |
5 (15.2) |
Cholesterol lowering drugs |
55 (40.7) |
48 (47.1) |
7
(21.2) |
NSAR |
12 (8.9) |
11 (10.8) |
1 (3.0) |
Opioids |
17 (12.6) |
14 (13.7) |
3 (9.1) |
Uric acid lowering drugs |
5 (3.7) |
3 (2.9) |
2 (6.1) |
Benzodiazepines |
18 (13.3) |
14 (13.7) |
4 (12.1) |
Antidepressants |
28 (20.7) |
24 (23.5) |
4 (12.1) |
Antipsychotics |
10 (7.4) |
9 (8.8) |
1 (3.0) |
Antiepileptics |
9 (6.7) |
8 (7.8) |
1 (3.0) |
Antidiabetics |
22 (16.3) |
17 (16.7) |
5 (15.2) |
Tamoxifen |
12 (8.9) |
12 (11.8) |
0 (0) |
CYP2C19 Inhibitor3
|
11 (8.2) |
10 (9.8) |
1
(3.0) |
CYP2D6 Inhibitor3
|
26 (19.3) |
20 (19.6) |
6
(18.2) |